1. US Food and Drug Administration. Investigational new drug (IND) application.
[online]
, (2014).
2. Jarow, J. P., Casak, S., Chuk, M., Ehrlich, L. A. & Khozin, S. The majority of expedited investigational new drug safety reports are uninformative. Clin. Cancer Res.
http://dx.doi.org/10.1158/1078-0432.CCR-15-2082
, (2016).
3. US Department of Health and Human Services. Guidance for industry and investigator safety reporting requirements for INDs and BA/BE studies. US Food and Drug Administration
[online]
, (2012).
4. [No authors listed.] Investigational new drug safety reporting: advancing CTTI recommendations. Clinical Trials Transformation Initiative
[online]
, (2016).
5. US Department of Health and Human Services. Safety assessment for IND safety reporting guidance for industry. US Food and Drug Administration
[online]
, (2015).